Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,397 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Terminated Phase 1Phase 2 Interventional Results available

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

NCT02457910
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 30, 2026, 1:25 PM EDT
Terminated Phase 1 Interventional

Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors

NCT00804310
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone, lapatinib ditosylate
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

NCT00116506
View directory record Official record
Conditions
Colorectal Cancer, Neoplasm Metastasis
Interventions
erlotinib, FOLFOX, bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Faricimab in Patients With NPDR

NCT05681884
View directory record Official record
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
Faricimab
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Bakersfield, California • Modesto, California • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 3 Interventional

I Change Adherence & Raise Expectations

NCT01232478
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Comprehensive Adherence Program (CAP)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
11 Years to 20 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 30, 2026, 1:25 PM EDT
Active, not recruiting Phase 2 Interventional

Emicizumab in Patients With Acquired Hemophilia A

NCT05345197
View directory record Official record
Conditions
Acquired Hemophilia A
Interventions
emicizumab
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
San Diego, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects

NCT03796013
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Entrectinib Form A, Entrectinib Form C
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Results available

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

NCT00076310
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, OSI-774, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 1:25 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles

NCT02142114
View directory record Official record
Conditions
Pain
Interventions
Eye injection by 30 or 32 gauge needle
Device
Lead sponsor
Retina Health Center
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 30, 2026, 1:25 PM EDT
Active, not recruiting Phase 2 Interventional

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

NCT04447768
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Obinutuzumab, Venetoclax
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

NCT03815058
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Autogene cevumeran, Pembrolizumab
Biological · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
17
States / cities
Duarte, California • La Jolla, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

NCT00580333
View directory record Official record
Conditions
Breast Cancer
Interventions
cisplatin, bevacizumab, doxorubicin, cyclophosphamide, paclitaxel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional

Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

NCT00161291
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole in combination with Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 4, 2011 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional

Avastin and Taxotere for Esophagogastric Cancer

NCT00137813
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Docetaxel, Bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 30, 2026, 1:25 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

NCT01889797
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphoma
Interventions
Arm A: Rituximab, Arm B: GA101
Biological
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
28
States / cities
Mobile, Alabama • Greenbrae, California • Savannah, Georgia + 25 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

NCT01363947
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Ovarian Cancer
Interventions
DNIB0600A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas

NCT02639117
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Vismodegib
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 30, 2026, 1:25 PM EDT
Withdrawn Phase 2 Interventional

Lenalidomide and Obinutuzumab for Previously Untreated CLL

NCT02371590
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lenalidomide, Obinutuzumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

NCT00130728
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
bevacizumab, erlotinib HCl, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
4
States / cities
Vallejo, California • Athens, Georgia • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Results available

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

NCT00193492
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Bevacizumab, Rituximab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
22
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors

NCT02366312
View directory record Official record
Conditions
Keratocystic Odontogenic Tumor
Interventions
vismodegib
Drug
Lead sponsor
NYU College of Dentistry
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 30, 2026, 1:25 PM EDT
Completed Phase 2 Interventional

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

NCT00142467
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Gemcitabine, Oxaliplatin, Bevacizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 30, 2026, 1:25 PM EDT
Terminated Phase 2 Interventional

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT01057212
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
ixabepilone, bevacizumab
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 30, 2026, 1:25 PM EDT
Recruiting Phase 1Phase 2 Interventional

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

NCT05987644
View directory record Official record
Conditions
Lung Cancer, NSCLC, Brain Metastases
Interventions
Alectinib, Stereotactic Radiosurgery
Drug · Radiation
Lead sponsor
Joshua Palmer
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 1:25 PM EDT